RecruitingPHASE1, PHASE2NCT05761899
Safety and Efficacy of PMT Therapy of hPAP
Studying Hereditary pulmonary alveolar proteinosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- Christopher Towe, MDChildren's Hospital Medical Center, Cincinnati
- Intervention
- Gene-Corrected Macrophages administered by bronchoscopic instillation(combination_product)
- Enrollment
- 3 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2038
Study locations (1)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · University of South Florida
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05761899 on ClinicalTrials.gov